Mehrsa Jalalizadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mehrsa Jalalizadeh has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Leonardo Oliveira Reis
UroScience and Department of Surgery (Urology), School of Medical Sciences, University of Campinas, Unicamp, and Pontifical Catholic University of Campinas, PUC-Campinas, Campinas, São Paulo, Brazil
23 shared publications - Etsuko Miyagi
Department of Obstetrics and Gynecology, Yokohama City University Graduate School of Medicine
19 shared publications Guiyang Jiang
19 shared publications- Hiroshi Miyamoto
Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, USA
19 shared publications - Ikuma Kato
Department of Molecular Pathology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
19 shared publications - Mitsunori Fukuda
Tohoku University
19 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Although intravesical bacillus Calmette-Guérin (BCG) immunotherapy has been the gold standard for nonsurgical management of non–muscle-invasive bladder cancer, a considerable number of patients exhibit resistance to the adjuvant treatment with unexplained mechanisms. This study aimed to investigate whether and how androgen receptor (AR) signals modulate BCG cytotoxicity in bladder cancer. AR knockdown or overexpression in bladder cancer lines resulted in induction or reduction, respectively, in intracellular BCG quantity and its cytotoxic activity. Microarray screening identified Rab27b, a small GTPase known to mediate bacterial exocytosis, which was upregulated in BCG-resistant cells and downregulated in AR-shRNA cells. Knockdown of Rab27b, or its effector SYTL3, or overexpression of Rab27b also induced or reduced, respectively, BCG quantity and cytotoxicity. In addition, treatment with GW4869, which was previously shown to inhibit Rab27b-dependent secretion, induced them and reduced Rab27b expression in bladder cancer cells. Meanwhile, AR expression was upregulated in BCG-resistant lines, compared with respective controls. In a mouse orthotopic xenograft model, Rab27b/SYTL3 knockdown or GW4869 treatment enhanced the amount of BCG within tumors and its suppressive effect on tumor growth. Moreover, in non–muscle-invasive bladder cancer specimens from patients subsequently undergoing BCG therapy, positivity of AR/Rab27b expression was associated with significantly higher risks of tumor recurrence. AR activation thus correlates with resistance to BCG treatment, presumably via upregulating Rab27b expression. Mechanistically, it is suggested that BCG elimination from urothelial cells is induced by Rab27b/SYTL3-mediated exocytosis. Accordingly, Rab27b inactivation, potentially via antiandrogenic drugs and/or exocytosis inhibition are anticipated to sensitize the efficacy of BCG therapy, especially in patients with BCG-refractory AR/Rab27b-positive bladder cancer.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Although intravesical bacillus Calmette-Guérin (BCG) immunotherapy has been the gold standard for nonsurgical management of non–muscle-invasive bladder cancer, a considerable number of patients exhibit resistance to the adjuvant treatment with unexplained mechanisms. This study aimed to investigate whether and how androgen receptor (AR) signals modulate BCG cytotoxicity in bladder cancer. AR knockdown or overexpression in bladder cancer lines resulted in induction or reduction, respectively, in intracellular BCG quantity and its cytotoxic activity. Microarray screening identified Rab27b, a small GTPase known to mediate bacterial exocytosis, which was upregulated in BCG-resistant cells and downregulated in AR-shRNA cells. Knockdown of Rab27b, or its effector SYTL3, or overexpression of Rab27b also induced or reduced, respectively, BCG quantity and cytotoxicity. In addition, treatment with GW4869, which was previously shown to inhibit Rab27b-dependent secretion, induced them and reduced Rab27b expression in bladder cancer cells. Meanwhile, AR expression was upregulated in BCG-resistant lines, compared with respective controls. In a mouse orthotopic xenograft model, Rab27b/SYTL3 knockdown or GW4869 treatment enhanced the amount of BCG within tumors and its suppressive effect on tumor growth. Moreover, in non–muscle-invasive bladder cancer specimens from patients subsequently undergoing BCG therapy, positivity of AR/Rab27b expression was associated with significantly higher risks of tumor recurrence. AR activation thus correlates with resistance to BCG treatment, presumably via upregulating Rab27b expression. Mechanistically, it is suggested that BCG elimination from urothelial cells is induced by Rab27b/SYTL3-mediated exocytosis. Accordingly, Rab27b inactivation, potentially via antiandrogenic drugs and/or exocytosis inhibition are anticipated to sensitize the efficacy of BCG therapy, especially in patients with BCG-refractory AR/Rab27b-positive bladder cancer.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S6 from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Effects of Rab27b overexpression or knockdown on the expression of AR, Rab27a, and SYTL3, as well as fibronectin/integrin and macropinocytosis-related molecules, in bladder cancer cells.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Effects of Rab27b overexpression or knockdown on the expression of AR, Rab27a, and SYTL3, as well as fibronectin/integrin and macropinocytosis-related molecules, in bladder cancer cells.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Effects of Rab27b/SYTL3 knockdown or GW4869 treatment on the proliferation of bladder cancer cells.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Effects of Rab27b/SYTL3 knockdown or GW4869 treatment on the proliferation of bladder cancer cells.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Effects of androgen on BCG cytotoxicity in bladder cancer cells.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Effects of androgen on BCG cytotoxicity in bladder cancer cells.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Immunofluorescence of BCG in bladder cancer cells.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Immunofluorescence of BCG in bladder cancer cells.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S6 from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Effects of Rab27b overexpression or knockdown on the expression of AR, Rab27a, and SYTL3, as well as fibronectin/integrin and macropinocytosis-related molecules, in bladder cancer cells.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Effects of Rab27b overexpression or knockdown on the expression of AR, Rab27a, and SYTL3, as well as fibronectin/integrin and macropinocytosis-related molecules, in bladder cancer cells.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Immunofluorescence of BCG in bladder cancer cells.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Immunofluorescence of BCG in bladder cancer cells.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Effects of androgen on BCG cytotoxicity in bladder cancer cells.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis
Effects of androgen on BCG cytotoxicity in bladder cancer cells.